AAPL311.00+1.62 (+0.52%) ▲|ABBV246.20+2.40 (+0.98%) ▲|ABT105.71+0.25 (+0.24%) ▲|ACN170.73+0.30 (+0.18%) ▲|ADBE259.32+1.83 (+0.71%) ▲|AMAT534.24-12.38 (-2.26%) ▼|AMD482.05-36.53 (-7.04%) ▼|AMGN407.83+17.81 (+4.57%) ▲|AMT168.07-7.18 (-4.10%) ▼|AMZN272.65-4.77 (-1.72%) ▼|AVGO418.28+0.12 (+0.03%) ▲|AXP348.99+2.28 (+0.66%) ▲|BA240.19+3.03 (+1.28%) ▲|BAC63.25+0.35 (+0.56%) ▲|BKNG207.02+12.75 (+6.56%) ▲|BLK1,133.58+2.45 (+0.22%) ▲|BMY63.63-2.26 (-3.43%) ▼|BNY158.74+1.92 (+1.22%) ▲|BRK-B518.85+1.63 (+0.32%) ▲|C137.64+0.77 (+0.56%) ▲|CAT871.08-5.46 (-0.62%) ▼|CL93.28+0.75 (+0.81%) ▲|CMCSA24.75-0.18 (-0.72%) ▼|COF221.63-0.28 (-0.13%) ▼|COP115.04-2.90 (-2.46%) ▼|COST941.99-5.86 (-0.62%) ▼|CRM192.98+1.99 (+1.04%) ▲|CSCO121.50-0.24 (-0.20%) ▼|CVS99.12-5.30 (-5.08%) ▼|CVX186.41-3.99 (-2.10%) ▼|DE612.00-5.37 (-0.87%) ▼|DHR199.66+4.88 (+2.51%) ▲|DIS101.76+3.58 (+3.65%) ▲|DUK123.34-0.93 (-0.75%) ▼|EMR162.47+3.63 (+2.29%) ▲|FDX310.72-2.62 (-0.84%) ▼|GD384.08-1.68 (-0.44%) ▼|GE381.22+3.94 (+1.04%) ▲|GEV1,017.96-0.57 (-0.06%) ▼|GILD131.76-3.49 (-2.58%) ▼|GM89.16+0.85 (+0.96%) ▲|GOOG360.13-15.22 (-4.05%) ▼|GOOGL362.43-15.22 (-4.03%) ▼|GS1,060.38+7.40 (+0.70%) ▲|HD353.14+4.90 (+1.41%) ▲|HON248.12-0.67 (-0.27%) ▼|IBM235.92+0.77 (+0.33%) ▲|INTC101.06+0.20 (+0.20%) ▲|INTU327.94+4.34 (+1.34%) ▲|ISRG375.20+6.94 (+1.88%) ▲|JNJ257.59+2.66 (+1.04%) ▲|JPM359.24+1.72 (+0.48%) ▲|KO86.83+0.27 (+0.31%) ▲|LIN491.05+6.41 (+1.32%) ▲|LLY1,169.86+54.18 (+4.86%) ▲|LMT577.60-11.73 (-1.99%) ▼|LOW219.94+1.86 (+0.85%) ▲|LRCX307.42-10.32 (-3.25%) ▼|MA570.48-0.62 (-0.11%) ▼|MCD274.00+5.66 (+2.11%) ▲|MDLZ62.60+0.52 (+0.84%) ▲|MDT85.99-0.21 (-0.24%) ▼|META588.77+0.83 (+0.14%) ▲|MMM182.08+0.63 (+0.35%) ▲|MO68.44+0.37 (+0.54%) ▲|MRK128.33+0.33 (+0.26%) ▲|MS218.27+1.23 (+0.57%) ▲|MSFT487.46-5.35 (-1.09%) ▼|MU893.19+0.52 (+0.06%) ▲|NEE85.91-1.29 (-1.48%) ▼|NFLX74.20+0.63 (+0.86%) ▲|NKE42.45+0.92 (+2.22%) ▲|NOW117.22-0.92 (-0.78%) ▼|NVDA219.22+7.28 (+3.43%) ▲|ORCL144.39-1.35 (-0.93%) ▼|PEP138.78-0.32 (-0.23%) ▼|PFE25.81+0.40 (+1.57%) ▲|PG146.80-1.21 (-0.82%) ▼|PLTR158.43-4.23 (-2.60%) ▼|PM188.93+2.02 (+1.08%) ▲|QCOM157.53-5.14 (-3.16%) ▼|RTX222.31+4.38 (+2.01%) ▲|SBUX106.00+1.03 (+0.98%) ▲|SCHW108.02+1.67 (+1.57%) ▲|SO93.10-0.15 (-0.16%) ▼|SPG224.81-1.09 (-0.48%) ▼|T23.06-0.32 (-1.37%) ▼|TMO577.83+13.08 (+2.32%) ▲|TMUS173.46-3.75 (-2.12%) ▼|TSLA321.55-5.80 (-1.77%) ▼|TXN277.72-5.91 (-2.08%) ▼|UBER68.18-3.81 (-5.29%) ▼|UNH412.75+5.20 (+1.28%) ▲|UNP295.54-0.81 (-0.27%) ▼|UPS107.70-1.41 (-1.29%) ▼|USB64.21-0.02 (-0.03%) ▼|V368.54-1.05 (-0.28%) ▼|VZ46.47-0.41 (-0.87%) ▼|WFC89.17+0.78 (+0.88%) ▲|WMT112.34+0.79 (+0.71%) ▲|XOM151.63-2.33 (-1.51%) ▼|AAPL311.00+1.62 (+0.52%) ▲|ABBV246.20+2.40 (+0.98%) ▲|ABT105.71+0.25 (+0.24%) ▲|ACN170.73+0.30 (+0.18%) ▲|ADBE259.32+1.83 (+0.71%) ▲|AMAT534.24-12.38 (-2.26%) ▼|AMD482.05-36.53 (-7.04%) ▼|AMGN407.83+17.81 (+4.57%) ▲|AMT168.07-7.18 (-4.10%) ▼|AMZN272.65-4.77 (-1.72%) ▼|AVGO418.28+0.12 (+0.03%) ▲|AXP348.99+2.28 (+0.66%) ▲|BA240.19+3.03 (+1.28%) ▲|BAC63.25+0.35 (+0.56%) ▲|BKNG207.02+12.75 (+6.56%) ▲|BLK1,133.58+2.45 (+0.22%) ▲|BMY63.63-2.26 (-3.43%) ▼|BNY158.74+1.92 (+1.22%) ▲|BRK-B518.85+1.63 (+0.32%) ▲|C137.64+0.77 (+0.56%) ▲|CAT871.08-5.46 (-0.62%) ▼|CL93.28+0.75 (+0.81%) ▲|CMCSA24.75-0.18 (-0.72%) ▼|COF221.63-0.28 (-0.13%) ▼|COP115.04-2.90 (-2.46%) ▼|COST941.99-5.86 (-0.62%) ▼|CRM192.98+1.99 (+1.04%) ▲|CSCO121.50-0.24 (-0.20%) ▼|CVS99.12-5.30 (-5.08%) ▼|CVX186.41-3.99 (-2.10%) ▼|DE612.00-5.37 (-0.87%) ▼|DHR199.66+4.88 (+2.51%) ▲|DIS101.76+3.58 (+3.65%) ▲|DUK123.34-0.93 (-0.75%) ▼|EMR162.47+3.63 (+2.29%) ▲|FDX310.72-2.62 (-0.84%) ▼|GD384.08-1.68 (-0.44%) ▼|GE381.22+3.94 (+1.04%) ▲|GEV1,017.96-0.57 (-0.06%) ▼|GILD131.76-3.49 (-2.58%) ▼|GM89.16+0.85 (+0.96%) ▲|GOOG360.13-15.22 (-4.05%) ▼|GOOGL362.43-15.22 (-4.03%) ▼|GS1,060.38+7.40 (+0.70%) ▲|HD353.14+4.90 (+1.41%) ▲|HON248.12-0.67 (-0.27%) ▼|IBM235.92+0.77 (+0.33%) ▲|INTC101.06+0.20 (+0.20%) ▲|INTU327.94+4.34 (+1.34%) ▲|ISRG375.20+6.94 (+1.88%) ▲|JNJ257.59+2.66 (+1.04%) ▲|JPM359.24+1.72 (+0.48%) ▲|KO86.83+0.27 (+0.31%) ▲|LIN491.05+6.41 (+1.32%) ▲|LLY1,169.86+54.18 (+4.86%) ▲|LMT577.60-11.73 (-1.99%) ▼|LOW219.94+1.86 (+0.85%) ▲|LRCX307.42-10.32 (-3.25%) ▼|MA570.48-0.62 (-0.11%) ▼|MCD274.00+5.66 (+2.11%) ▲|MDLZ62.60+0.52 (+0.84%) ▲|MDT85.99-0.21 (-0.24%) ▼|META588.77+0.83 (+0.14%) ▲|MMM182.08+0.63 (+0.35%) ▲|MO68.44+0.37 (+0.54%) ▲|MRK128.33+0.33 (+0.26%) ▲|MS218.27+1.23 (+0.57%) ▲|MSFT487.46-5.35 (-1.09%) ▼|MU893.19+0.52 (+0.06%) ▲|NEE85.91-1.29 (-1.48%) ▼|NFLX74.20+0.63 (+0.86%) ▲|NKE42.45+0.92 (+2.22%) ▲|NOW117.22-0.92 (-0.78%) ▼|NVDA219.22+7.28 (+3.43%) ▲|ORCL144.39-1.35 (-0.93%) ▼|PEP138.78-0.32 (-0.23%) ▼|PFE25.81+0.40 (+1.57%) ▲|PG146.80-1.21 (-0.82%) ▼|PLTR158.43-4.23 (-2.60%) ▼|PM188.93+2.02 (+1.08%) ▲|QCOM157.53-5.14 (-3.16%) ▼|RTX222.31+4.38 (+2.01%) ▲|SBUX106.00+1.03 (+0.98%) ▲|SCHW108.02+1.67 (+1.57%) ▲|SO93.10-0.15 (-0.16%) ▼|SPG224.81-1.09 (-0.48%) ▼|T23.06-0.32 (-1.37%) ▼|TMO577.83+13.08 (+2.32%) ▲|TMUS173.46-3.75 (-2.12%) ▼|TSLA321.55-5.80 (-1.77%) ▼|TXN277.72-5.91 (-2.08%) ▼|UBER68.18-3.81 (-5.29%) ▼|UNH412.75+5.20 (+1.28%) ▲|UNP295.54-0.81 (-0.27%) ▼|UPS107.70-1.41 (-1.29%) ▼|USB64.21-0.02 (-0.03%) ▼|V368.54-1.05 (-0.28%) ▼|VZ46.47-0.41 (-0.87%) ▼|WFC89.17+0.78 (+0.88%) ▲|WMT112.34+0.79 (+0.71%) ▲|XOM151.63-2.33 (-1.51%) ▼|
26.2 C
New York
Wednesday, August 5, 2026

Tag: optic nerve damage

newssourceFORcompanyinformationcontent1releasesmarket

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOptic nerve damage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers